Elizabeth Alli, Ph.D.
Title | Assistant Professor |
---|
Institution | Wake Forest School of Medicine |
---|
Department | Cancer Biology |
---|
Address | |
---|
vCard | Download vCard |
---|
|
|
|
Biography University of Southern California, Los Angeles, CA | B.S. | 1995 | Exercise Science (major); Chemistry (minor) | Rutgers University-Biomedical and Health Sciences, New Brunswick, NJ | M.S. | 2001 | Molecular and Cellular Pharmacology | Rutgers University-Biomedical and Health Sciences, New Brunswick, NJ | Ph.D. | 2006 | Molecular and Cellular Pharmacology | Stanford University School of Medicine, Stanford, CA | Postdoc | 2011 | Medicine-Oncology |
2000 - 2000 | Young Investigator’s Award, UMDNJ-Department of Pharmacology | 2001 - 2001 | Gallo Award for Cancer Research, State of New Jersey | 2002 - 2002 | Award for Scientific Excellence, State of New Jersey | 2005 - 2005 | Merck Scholar-in-Training Award, American Association for Cancer Research | 2007 - 2007 | Dean’s Postdoctoral Fellowship, Stanford University School of Medicine | 2007 - 2007 | Helena Anna Henzl Gabor Young Women in Science Travel Award, Stanford University School of Medicine | 2008 - 2008 | Bristol-Myers Squibb Oncology Scholar-in-Training Award, American Association for Cancer Research | 2009 - 2009 | Helena Anna Henzl Gabor Young Women in Science Travel Award, Stanford University School of Medicine | 2010 - 2010 | Helena Anna Henzl Gabor Young Women in Science Travel Award, Stanford University School of Medicine | 2014 - 2014 | Susan G. Komen Scholar-in-Training Award, American Association for Cancer Research | 2015 - 2016 | Spark Scholar Award, Stanford University School of Medicine | 2015 - 2019 | K22 Transition Career Development Award, NIH/NCI | 2008 - 2011 | Postdoctoral Fellowship Award , Susan G. Komen Foundation | 2017 - 2017 | Concept Award, Wake Forest School of Medicine | 2017 - 2018 | Daryl and Marguerite Errett Discovery Award, Errett Fisher Foundation |
Overview Research K22CA181550 (ALLI, ELIZABETH)Sep 15, 2015 - Aug 31, 2019 NIH Targeting defective DNA repair for the prevention of BRCA1-associated cancers Role: Principal Investigator |
| R01CA227261 (KELLY, DEBORAH F)Mar 1, 2018 - Feb 28, 2023 NIH Hot Spot Analysis of the Breast Cancer Susceptibility Protein Role: Co-Investigator |
| R01CA219700 (KELLY, DEBORAH F)Jun 1, 2018 - May 31, 2023 NIH Multi-scale imaging of breast cancer proteins during DNA repair Role: Co-Investigator |
Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
Faculty can login to make corrections and additions.
-
Liang Y, Dearnaley WJ, Alden NA, Solares MJ, Gilmore BL, Pridham KJ, Varano AC, Sheng Z, Alli E, Kelly DF. Correcting errors in the BRCA1 warning system. DNA Repair (Amst). 2019 01; 73:120-128. PMID: 30503669.
-
Alli E, Ford JM. BRCA1: Beyond double-strand break repair. DNA Repair (Amst). 2015 Aug; 32:165-171. PMID: 25956865.
-
Alli E, Ford JM. BRCA1: a movement toward cancer prevention. Mol Cell Oncol. 2015 Jul-Sep; 2(3):e979685. PMID: 27308455.
-
Alli E, Solow-Cordero D, Casey SC, Ford JM. Therapeutic targeting of BRCA1-mutated breast cancers with agents that activate DNA repair. Cancer Res. 2014 Nov 01; 74(21):6205-15. PMID: 25217519.
-
Vinayak S, Schwartz EJ, Jensen K, Lipson J, Alli E, McPherson L, Fernandez AM, Sharma VB, Staton A, Mills MA, Schackmann EA, Telli ML, Kardashian A, Ford JM, Kurian AW. A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk. Breast Cancer Res Treat. 2013 Nov; 142(2):389-98. PMID: 24166281.
-
Alli E, Ford JM. Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomol. DNA Repair (Amst). 2012 May 01; 11(5):522-4. PMID: 22425348.
-
Alli E, Sharma VB, Hartman AR, Lin PS, McPherson L, Ford JM. Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells. BMC Pharmacol. 2011 Jul 19; 11:7. PMID: 21771338.
-
Hastak K, Alli E, Ford JM. Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer Res. 2010 Oct 15; 70(20):7970-80. PMID: 20798217.
-
Alli E, Sharma VB, Sunderesakumar P, Ford JM. Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. Cancer Res. 2009 Apr 15; 69(8):3589-96. PMID: 19351835.
-
Alli E, Yang JM, Ford JM, Hait WN. Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells. Mol Pharmacol. 2007 May; 71(5):1233-40. PMID: 17272681.
-
Hait WN, Rubin E, Alli E, Goodin S. Tubulin . Tubulin Targeting Agents. Update on Cancer Therapeutics. 2007; 2(1):1-18.
-
Alli E, Yang JM, Hait WN. Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53. Oncogene. 2007 Feb 15; 26(7):1003-12. PMID: 16909102.
-
Alli E, Bash-Babula J, Yang JM, Hait WN. Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer. Cancer Res. 2002 Dec 01; 62(23):6864-9. PMID: 12460900.
-
Bash-Babula J, Toppmeyer D, Labassi M, Reidy J, Orlick M, Senzon R, Alli E, Kearney T, August D, Shih W, Yang JM, Hait WN. A Phase I/pilot study of sequential doxorubicin/vinorelbine: effects on p53 and microtubule-associated protein 4. Clin Cancer Res. 2002 May; 8(5):1057-64. PMID: 12006519.
This graph shows the total number of publications by year, by first, middle/unknown, or last author.
To see the data from this visualization as text, click here.
Year | Publications |
---|
2002 | 2 | 2006 | 1 | 2007 | 2 | 2009 | 1 | 2010 | 1 | 2011 | 1 | 2012 | 1 | 2013 | 1 | 2014 | 1 | 2015 | 2 | 2018 | 1 |
To return to the timeline, click here.
|
Alli's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|